Detalhe da pesquisa
1.
Safety and enhanced immunostimulatory activity of the DRD2 antagonist ONC201 in advanced solid tumor patients with weekly oral administration.
J Immunother Cancer
; 7(1): 136, 2019 05 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-31118108